Premium
Prognostic factors and treatment outcome in childhood hodgkin disease
Author(s) -
Oguz Aynur,
Karadeniz Ceyda,
Okur F. Visal,
Cıtak E. Caglar,
Pınarlı F. Guçlu,
Bora Huseyin,
Akyurek Nalan
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20487
Subject(s) - medicine , univariate analysis , multivariate analysis , stage (stratigraphy) , radiation therapy , disease , chemotherapy , prospective cohort study , univariate , oncology , lymph node , multivariate statistics , paleontology , statistics , mathematics , biology
Background The goals of this study included: (1) Identification of factors prognostic for event‐free survival (EFS) and overall survival (OS), and (2) Definition of risk groups for risk adapted therapy in children with Hodgkin disease (HD). Procedure From 1991 to 2003, 69 children with newly diagnosed, untreated biopsy‐proven stage I–IV HD were treated with chemotherapy (CT) and low‐dose involved field radiotherapy (LD‐IFRT). The relationship of pretreatment factors to EFS and OS was analyzed by univariate and multivariate analysis. Results The 5‐year EFS and OS for all patients were 90.77% and 96.22%, respectively with a median follow‐up of 73 months (3–137 months). Male to female ratio was 3:1 and 21 children (32.3%) were less than 7 years of age. Mixed cellularity was the predominant histologic subtype (38.5%). Factors associated with inferior EFS by univariate analysis were extranodal disease, hemoglobin level <11 g/dl, number of involved lymph node regions and stage. By multivariate analysis only stage IV disease was significant. Conclusion Our study confirms that excellent results are achievable with combined modality therapy in childhood HD. In order to use risk‐adapted therapy in children with HD, clinical prognostic factors should be validated with large, multicentered prospective clinical studies. © 2005 Wiley‐Liss, Inc.